Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 501 to 525 of 872

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis	TA590	31 July 2019	31 July 2019
Letermovir for preventing cytomegalovirus disease after a stem cell transplant	TA591	31 July 2019	31 July 2019
Nusinersen for treating spinal muscular atrophy	TA588	24 July 2019	24 July 2019
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	TA589	24 July 2019	24 July 2019
Bisphosphonates for treating osteoporosis	TA464	9 August 2017	8 July 2019
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies	TA171	18 June 2009	26 June 2019
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality	TA322	24 September 2014	26 June 2019
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib	TA586	26 June 2019	26 June 2019
Lenalidomide plus dexamethasone for previously untreated multiple myeloma	TA587	26 June 2019	26 June 2019
Ocrelizumab for treating primary progressive multiple sclerosis	TA585	12 June 2019	12 June 2019
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes	TA583	5 June 2019	5 June 2019
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer	TA584	5 June 2019	5 June 2019
Enzalutamide for hormone-relapsed non-metastatic prostate cancer	TA580	15 May 2019	15 May 2019
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma	TA577	24 April 2019	24 April 2019
Certolizumab pegol for treating moderate to severe plaque psoriasis	TA574	17 April 2019	17 April 2019
Tildrakizumab for treating moderate to severe plaque psoriasis	TA575	17 April 2019	17 April 2019
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)	TA576	17 April 2019	17 April 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes	TA572	27 March 2019	27 March 2019
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer	TA569	20 March 2019	20 March 2019
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)	TA570	20 March 2019	20 March 2019
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib	TA571	20 March 2019	20 March 2019
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)	TA568	13 March 2019	13 March 2019
Cochlear implants for children and adults with severe to profound deafness	TA566	7 March 2019	7 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	TA563	27 February 2019	27 February 2019
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia	TA561	27 February 2019	27 February 2019

Results per page

10
25
50
All